Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

136.79 +4.45 (+3.36%)
Official Closing Price Updated: 7:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,779,521
Open 135.75
Bid (Size) 134.87 (1)
Ask (Size) 138.34 (1)
Prev. Close 132.34
Today's Range 135.26 - 137.43
52wk Range 94.75 - 157.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
The 7 ETFs to Buy for the Perfect Portfolio
These seven ETFs to buy provide investors with an easily manageable portfolio that delivers good risk-adjusted returns over the long haul. 
Via InvestorPlace

Performance

YTD
-0.12%
-0.12%
1 Month
+0.01%
+0.01%
3 Month
+21.69%
+21.69%
6 Month
+32.55%
+32.55%
1 Year
+30.74%
+30.74%

More News

Read More
Novo Nordisk A/s (NVO) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
Novo Nordisk Earnings Preview
Via Benzinga
$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Via Benzinga
2 Top Biotech Stocks Defying the Bear Market
Via The Motley Fool
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
Via Investor's Business Daily
Novo Nordisk Q4 Highlights: Clocks 25% Increase In Sales On Strong Diabetes and Obesity Treatment, Expects 13% - 19% Revenue Growth
Via Benzinga
7 Healthcare Stocks That Will Be Big Winners in 2023
Via InvestorPlace
3 Global Stocks to Buy to Get Around America’s Slowdown
Via InvestorPlace
Mr. Beast Video Highlights Major Problem: Billions Will Need Eyecare According To Report
Via Benzinga
Earnings Scheduled For February 1, 2023
Via Benzinga
2 Market-Beating Stocks to Buy in 2023 and Hold for 10 Years
Via The Motley Fool
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
Via Benzinga
3 Drug Stocks With Promising Pipelines for 2023
Via InvestorPlace
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
Via Benzinga
Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19
Via Benzinga
How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly
Via Investor's Business Daily
EXL Announces Appointment of Andreas Fibig to Board of Directors
From ExlService Holdings, Inc.
Via Globe NewsWire
Sharps Technology Is Injecting A Better Solution Into The Healthcare Syringe Industry
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
Global Drug Delivery Systems Market Size Projected to Reach $71.75 Billion By 2029
Via FinancialNewsMedia
Exposures COVID-19
Jim Cramer Says Avoid This Stock: 'Too Expensive'
Via Benzinga
Could Eli Lilly Stock Help You Become a Millionaire?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.